17.35
-0.08(-0.46%)
Currency In USD
| Previous Close | 17.43 |
| Open | 17.67 |
| Day High | 18.12 |
| Day Low | 16.81 |
| 52-Week High | 18.12 |
| 52-Week Low | 3.73 |
| Volume | 427,107 |
| Average Volume | 2.06M |
| Market Cap | 845.69M |
| PE | -3.51 |
| EPS | -4.95 |
| Moving Average 50 Days | 8.35 |
| Moving Average 200 Days | 6.3 |
| Change | -0.08 |
If you invested $1000 in uniQure N.V. (QURE) 10 years ago, it would be worth $1,158.98 as of December 26, 2024 at a share price of $17.35. Whereas If you bought $1000 worth of uniQure N.V. (QURE) shares 5 years ago, it would be worth $232.51 as of December 26, 2024 at a share price of $17.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
GlobeNewswire Inc.
Dec 10, 2024 12:05 PM GMT
~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~ ~ FDA agrees
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
GlobeNewswire Inc.
Nov 21, 2024 12:05 PM GMT
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
GlobeNewswire Inc.
Nov 05, 2024 12:05 PM GMT
~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington’s disease ~ ~ Presented positive interim data from Phase I/II trial o